Clinical Trial Update: Post Hematopoietic Stem Cell Transplantation [Phase 4]

View source ↗

Summary

Novartis-sponsored Phase 4 trial evaluating iron overload after hematopoietic stem cell transplantation in patients with beta-thalassemia major has completed, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major | Phase 4 | Status: COMPLETED | Results posted: 2016-07-21